Nasdaq Markets

(RTTNews) - Swiss drug maker Roche Group (RHHBY) announced Friday the launch of its Elecsys Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark.

(RTTNews) - Indian shares opened on a positive note Friday despite U.S. and European markets ending on a downbeat note overnight. Asian markets elsewhere remain mostly higher despite worries about a faltering economic recovery.

The Zacks Tobacco industry is likely to gain from the rising demand for low risk products such as vaping, e-cigarettes and heat-not-burn variants. These products, owing to their beneficial claims, are largely being accepted by those looking to quit or reduce cigarette consumptio

HONG KONG (Reuters Breakingviews) - The streets of China are getting paved with baijiu. Chinese liquor titan Kweichow Moutai plans to issue bonds to help buy highway operator Guizhou Expressway from the struggling local government. This ludicrous diversification erased $

(RTTNews) - Asian stock markets are mostly higher on Friday with modest gains following the negative cues overnight from Wall Street reflecting weakness in tech stocks. Some of the markets pared early gains as investors preferred to remain on the sidelines amid worries about the

Wednesday was a good day for investors of biotech Arrowhead Pharmaceuticals (ARWR). Shares took off to the tune of 40% following the release of positive trial data.

In the Phase 2 open-label trial (AROAAT2002) assessing ARO-AAT for the rare genetic liver disease associated with alpha one antitrypsin deficiency (AATD), the treatment displayed convincing proof of a significant pharmacodynamic effect on AATD patients resulting in improvements in relevant biomarkers  following 24 weeks of treatment.

For H.C. Wainwright analyst Patrick Trucchio, the results are the latest addition to a pipeline “firing on all cylinders.”

The previous several weeks have seen positive updates on several noteworthy programs including ARO-APOC3 for high triglycerides (HTG), ARO-ANG3 for mixed dyslipidemia, and from JNJ-3989, Arrowhead’s collaboration with Janssen on a treatment for chronic hepatitis B virus (CHB) infection. The rest of 2020 looks promising too, with the anticipation of further data readouts from the pipeline.

In fact, the analyst counts Arrowhead as one of the investment firm’s “favorite picks” and continues to believe “ARO-AAT is likely to emerge as the first therapeutic for the liver disease phenotype of AATD.”

Expanding on this, Trucchio said, “We think the very positive outcome in the Phase 2 open-label trial  could drive increased enthusiasm among the alpha one community including patients, accelerating Arrowhead’s program; moreover, we think Arrowhead could seek to accelerate the program through discussions with the FDA, with Breakthrough Therapy designation among the possibilities... Eventually, we think the Street’s attention could shift to the cardio-metabolic programs, particularly ARO-APOC3 and AROANG3 as these programs continue to generate data at appropriate venues in 2H20 and advance in development.”

Overall, Trucchio gives ARO-AAT a 60% possibility of success. The full data set should get an airing at the AASLD (American Association for the Study of Liver Diseases) meeting in November.

Accordingly, Trucchio keeps a Buy rating on ARWR shares along with a $90 price target. Even after Wednesday’s surge, there remains strong upside of 97%, should Trucchio’s thesis play out over the coming months. (To watch Trucchio’s track record, click here)

Barring one analyst who has a Hold on ARWR shares, all 5 others to have posted a review over the last 3 months, recommend the stock a Buy. While not quite as bullish as the H.C. Wainwright's forecast, the $69 average price target could still yield returns of 51% in the year ahead. (See ARWR stock analysis on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

In this episode of Rule Breaker Investing: Review-a-palooza! The Motley Fool co-founder David Gardner is joined by The Motley Fool's Maria Gallagher to review 10 stock recommendations from past 5-Stock Samplers, including the first ever 5-Stock Sampler. Discover how these sample

(RTTNews) - Apple Inc. (AAPL) will launch an online store in India on September 23, offering the tech giant's full range of products and support directly to customers across the country for the first time.

(RTTNews) - Indian shares look set to open lower on Friday, tracking mixed Asian cues and a firmer dollar amid lingering worries about the global economic recovery. U.S. stocks ended lower overnight as weak jobless claims figures added to concerns that the economic recovery is

(RTTNews) - The Thai stock market on Thursday halted the two-day winning streak in which it had advanced more than 20 points or 1.6 percent. The Stock Exchange of Thailand now sits just beneath the 1,285-point plateau and the losses may accelerate on Friday.

(RTTNews) - The Japanese stock market slipped into negative territory on Friday after opening higher following the weak cues overnight from Wall Street and on worries about the global economic recovery.

It has been a tough year for Micron (MU), as the chipmaker has been heavily affected by adverse macro conditions. Yet, one analyst thinks the current share price could offer new investors an opportunity to get into MU on the cheap.

5-star Rosenblatt analyst Hans Mosesmann rates MU shares a Buy along with a $100 price target. This figure implies a 96% upside from current levels. (To watch Mosesmann’s track record, click here)

Mosesmann has longed banged the drum in Micron’s favor and looking ahead to the company’s August quarter (FQ4) earnings on September 29, Mosesmann implores investors snap up shares of the underperforming large-cap in anticipation of strong upside.

So, what’s behind Mosesmann’s confidence? The analyst explained, “We continue to like Micron on the long-term prospects of 5G smartphones, AI and machine learning applications, and a memory upcycle (2021 expected), where Micron is in one of its best positions to capture this upside.”

Ahead of the print, Mosesmann forecasts sales of $6 billion, a quarter-over-quarter increase of 10.3%, and non-GAAP EPS to hit $1.05, in-line with Micron's guidance.

The analyst counts “continued strength in data center (cloud and memory) from work-from-home related dynamics, new gaming consoles, and the start of a recovery in the smartphone market (5G) offset by weakness in enterprise” as the quarter’s main drivers.

However, Mosesmann’s confidence is tempered by lower expectations for the following quarter. The analyst sees a “downward bias versus current consensus revenue estimates of down high single-digits q/q,” believing the Street hasn’t fully taken into account the fact the company won’t be able to make any shipments to Huawei  - a client thought to make up almost 10% of Micron’s revenue - after September 14, due to the commencement of a U.S. ban on the Chinese telecom giant.

Nevertheless, Mosesmann counters the reduced outlook with the view that “overall bit demand/supply dynamics remain unchanged for a memory upcycle in 2021 driven by accelerated compute shifts, 5G, and WFH dynamics.”

While not quite as bullish, most of Mosesmann’s colleagues agree with his assessment. MU's Moderate Buy consensus rating is based on 17 Buys, 6 Holds and 1 Sell. With a $62.43 average price target, the analysts expect upside of 22.5% over the coming months. (See MU stock analysis on TipRanks)

To find good ideas for tech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

(RTTNews) - The Indonesia stock market has finished lower in three straight sessions, dropping more than 120 points or 2.4 percent along the way. The Jakarta Composite Index now sits just beneath the 5,040-point plateau and it's got another weak lead for Friday's trade.

Glucose biosensors are typically used by people with diabetes to track their blood sugar levels while avoiding traditional finger-stick tests that accomplish the same goal.

(RTTNews) - The Australian stock market edged lower after a positive start on Friday following the weak cues overnight from Wall Street as tech stocks slid for a second day. Worries about the economic recovery weighed on the market.

(RTTNews) - The Hong Kong stock market has moved lower in consecutive trading days, stumbling almost 400 points or 1.7 percent along the way. The Hang Seng Index now rests just above the 24,340-point plateau and it may extend its losses again on Friday.

(RTTNews) - Steel Dynamics Inc. (STLD) said it expects third quarter 2020 earnings to be in the range of $0.42 to $0.46 per share. Excluding certain items, the company expects third quarter 2020 adjusted earnings to be in the range of $0.46 to $0.50 per share. Analysts polled by

(RTTNews) - The China stock market has finished lower in two straight sessions, sliding more than 25 points or 0.7 percent along the way. The Shanghai Composite Index now sits just above the 3,270-point plateau and it may extend its losing streak on Friday.

Curaleaf Holdings (OTC: CURLF) has replaced one of its key executives. The company announced Thursday that it has named Talley Wettlaufer to the position of senior vice president of retail -- essentially the top manager of the company's growing retail network. The appointment is

(RTTNews) - The Taiwan stock market on Thursday ended the three-day winning streak in which it had jumped nearly 300 points or 2.4 percent. The Taiwan Stock Exchange now rests just above the 12,870-point plateau and it's looking at another red light for Friday's trade.